Sanofi (NASDAQ:SNY) Upgraded at Citigroup

Sanofi (NASDAQ:SNY) was upgraded by stock analysts at Citigroup to a “strong-buy” rating in a report released on Tuesday, Zacks.com reports.

Several other analysts have also commented on the stock. Argus increased their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 11th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Sanofi currently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Up 1.0 %

Shares of SNY opened at $57.47 on Tuesday. The firm has a market capitalization of $145.56 billion, a P/E ratio of 28.88, a P/E/G ratio of 1.60 and a beta of 0.60. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a fifty day moving average price of $54.08 and a 200-day moving average price of $50.35.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. During the same period in the prior year, the business earned $0.95 EPS. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. Equities research analysts expect that Sanofi will post 4.25 earnings per share for the current year.

Institutional Investors Weigh In On Sanofi

A number of hedge funds and other institutional investors have recently made changes to their positions in SNY. Cascade Investment Advisors Inc. grew its stake in Sanofi by 4.7% in the 1st quarter. Cascade Investment Advisors Inc. now owns 34,359 shares of the company’s stock valued at $1,670,000 after acquiring an additional 1,535 shares during the period. Vestal Point Capital LP purchased a new position in shares of Sanofi during the 4th quarter worth $14,919,000. Dynamic Advisor Solutions LLC raised its holdings in Sanofi by 39.2% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock valued at $2,780,000 after buying an additional 16,117 shares during the period. Manning & Napier Advisors LLC purchased a new stake in Sanofi in the 2nd quarter valued at about $13,725,000. Finally, Mount Yale Investment Advisors LLC raised its holdings in Sanofi by 44.3% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after buying an additional 12,806 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.